2023

Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, Reck M, Liersch
R, Kryzhanivska A, Oizumi S, Tanaka H, Hamm J, McCune SL, Bennett E, Gitlitz B,
McNally V, Ballinger M, McCleland M, Zou W, Das Thakur M, Novello S. Comparison
of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of
adjuvant atezolizumab in non-small cell lung cancer: results from the randomized
phase III IMpower010 trial. J Immunother Cancer. 2023 Oct;11(10):e007047. doi:
10.1136/jitc-2023-007047. PMID: 37903590; PMCID: PMC10619123.

Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D,
Moorahrend E, Sauer A, Bruch HR, Liersch R, Nusch A, Vehling-Kaiser U, Welslau
M, Grunewald R, Harich HD, Stephany M, Uhlig J, de Buhr R, Frank M, Hogrefe C,
Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I. Effectiveness,
safety and quality of life of trifluridine/tipiracil in pretreated patients with
metastatic colorectal cancer: Real-world data from the noninterventional TACTIC
study in Germany. Int J Cancer. 2023 Sep 15;153(6):1227-1240. doi:
10.1002/ijc.34603. Epub 2023 Jun 1. PMID: 37260368.

Steinmetz HT, Toczek-Thiel J, Lipke J, Liersch R, Sauer A, Tesch H, Heßling
J, Totzke U, Schmitz S. Time to first transfusion in lower-risk patients with
myelodysplastic neoplasia (MDS) is another prognostic factor of survival. Leuk
Lymphoma. 2023 Jul-Aug;64(8):1476-1479. doi: 10.1080/10428194.2023.2214649. Epub
2023 May 31. PMID: 37254711.

Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, Lerchenmueller
C, Reim D, Wahba R, Angele M, Heeg S, Keck T, Weimann A, Topp S, Piso P, Brandl
A, Schuele S, Jo P, Pratschke J, Wegel S, Rehders A, Moosmann N, Gaedcke J,
Heinemann V, Trips E, Loeffler M, Schlag PM, Thuss-Patience P. Effect of
Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric
Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867. Epub ahead of
print. PMID: 37906724.

Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M,
Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gröschl B,
Bachhuber P, Großer S, Pahl HL. Real-world analysis of ruxolitinib in
myelofibrosis: interim results focusing on patients who were naïve to JAK
inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Ann Hematol. 2023 Dec;102(12):3383-3399. doi: 10.1007/s00277-023-05458-1. Epub
2023 Oct 4. PMID: 37792065; PMCID: PMC10640411.

2022

Kutsch N, Pallasch C, Tausch E, Böhme V, Ritgen M, Liersch R, Wacker A,
Jacobs G, Trappe RU, Dreger P, Fischer K, Fink AM, Stilgenbauer S, Zhai S, Li B,
Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst BF. Efficacy
and Safety of the Combination of Tirabrutinib and Entospletinib With or Without
Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere. 2022 Mar
8;6(4):e692. doi: 10.1097/HS9.0000000000000692. PMID: 35284802; PMCID:
PMC8906452.

5: Sebastian M, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Liersch R, von
der Heyde E, Wiegand J, Ukena D, Bargon J, Schütte W, Riera-Knorrenschild J,
Fischer JR, Griesinger F, Allan V, Waldenberger D, Schumann C. Prospective,
Noninterventional Study of Nivolumab in Real-world Patients With Locally
Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy
(ENLARGE-Lung). J Immunother. 2022 Feb-Mar 01;45(2):89-99. doi:
10.1097/CJI.0000000000000397. PMID: 34908007.

Modest DP, Karthaus M, Kasper S, Moosmann N, Keitel V, Kiani A, Uhlig J,
Jacobasch L, Fischer V Weikersthal L, Fuchs M, Kaiser F, Lerchenmüller C, Sent
D, Junghanß C, Held S, Lorenzen S, Kaczirek K, Jung A, Stintzing S, Heinemann V.
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1
resection of RAS wild-type colorectal cancer liver metastases – The PARLIM trial
(AIO KRK 0314). Eur J Cancer. 2022 Sep;173:297-306. doi:
10.1016/j.ejca.2022.07.012. Epub 2022 Aug 12. PMID: 35970102.

Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A,
Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann
F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C,
Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line
treatment of older patients with RAS wild-type metastatic colorectal cancer: an
analysis of the randomised trial FIRE-3. Br J Cancer. 2022 Sep;127(5):836-843.
doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. PMID: 35637412; PMCID:
PMC9427779.

Hegewisch-Becker S, Kratz-Albers K, Wierecky J, Gerhardt S, Reschke D, Borchardt J, Reichelt R, Friedrich FW. Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Future Oncol. 2022 Dec 19. doi: 10.2217/fon-2022-0141. Online ahead of print. PMID: 36533962

2021

Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B,
Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M,
Morales L, Patel SL, Kaul M, Barata T, O’Shaughnessy J; IMpassion131
investigators. Primary results from IMpassion131, a double-blind, placebo-
controlled, randomised phase III trial of first-line paclitaxel with or without
atezolizumab for unresectable locally advanced/metastatic triple-negative breast
cancer. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801.
Epub 2021 Jul 1. PMID: 34219000.

Berdel AF, Schwöppe C, Brand C, Harrach S, Brömmel K, Hintelmann H, Lenz G,
Liersch R, Heinzow H, Schliemann C, Mesters RM, Berdel WE, Kessler T. Targeting
Tissue Factor to Tumor Vasculature to Induce Tumor Infarction. Cancers (Basel).
2021 Jun 7;13(11):2841. doi: 10.3390/cancers13112841. PMID: 34200318; PMCID:
PMC8201357.

Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker
F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U,
Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T,
Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C,
Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B,
Lenz G, Dreger P, Dietrich S. Polatuzumab vedotin as a salvage and bridging
treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul
13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. PMID: 34196677;
PMCID: PMC8288676.

Hirt C, Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R,
Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C,
Schlag R, Dierlamm J, Fischer von Weikersthal L, Ahmed A, Harich HD, Rosenwald
A, Klapper W, Dreyling M, Hiddemann W, Herold M. Rituximab Maintenance Versus
Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated
Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche
Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study
Group. Hemasphere. 2021 Jun 23;5(7):e600. doi: 10.1097/HS9.0000000000000600.
PMID: 34179697; PMCID: PMC8221804.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE,
Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M,
Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T,
Stintzing S. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal
cancer: final survival and per-protocol analysis of FIRE-3, a randomised
clinical trial. Br J Cancer. 2021 Feb;124(3):587-594. doi:
10.1038/s41416-020-01140-9. Epub 2020 Nov 6. PMID: 33154570; PMCID: PMC7851157.

Al-Batran SE, Hofheinz RD, Reichart A, Pauligk C, Schönherr C, Schlag R,
Siegler G, Dörfel S, Koenigsmann M, Zahn MO, Schubert J, Aldaoud A, Höffkes HG,
Schulz H, Hahn L, Uhlig J, Blau W, Stauch M, Weniger J, Wolf M, Jacobasch L,
Bildat S, Wehmeyer J, Homann N, Trojan J, Waidmann O, Fietz T, Feustel HP,
Groschek M, Wierecky J, Waibel K, Mahlmann S, Schwindel U, Peters U, Schuch G,
Pink D, Eschenburg H, Wörns MA, Harich HD, von Weikersthal LF, Däßler KU,
Behringer DM, Messmann H, Kretzschmar A, Gallmeier E, Forstbauer H, Kunzmann V,
Papke J, Büchner-Steudel P, Vehling-Kaiser U, Springfeld C, Vogel A, Ettrich TJ,
Schaaf M, Hausen GZ, Götze TO; Arbeitsgemeinschaft Internistische Onkologie
(AIO). Quality of life and outcome of patients with metastatic pancreatic cancer
receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life
results from the prospective QOLIXANE trial of the Platform for Outcome, Quality
of Life and Translational Research on Pancreatic Cancer registry. Int J Cancer.
2021 Mar 15;148(6):1478-1488. doi: 10.1002/ijc.33336. Epub 2020 Oct 23. PMID:
33038277.

2020

Barraco F, Greil R, Herbrecht R, Schmidt B, Reiter A, Willenbacher W,
Raymakers R, Liersch R, Wroclawska M, Pack R, Burock K, Karumanchi D, Gisslinger
H. Real-world non-interventional long-term post-authorisation safety study of
ruxolitinib in myelofibrosis. Br J Haematol. 2020 Dec;191(5):764-774. doi:
10.1111/bjh.16729. Epub 2020 Jun 24. PMID: 32583458.

Reinartz G, Molavi Tabrizi C, Liersch R, Ullerich H, Hering D, Willborn K,
Schultze J, Micke O, Ruebe C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M,
Moeller P, Neubauer A, Wilhelm M, Lenz G, Berdel WE, Willich N, Eich HT.
Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and
Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German
Multicenter Consecutive Prospective Phase II Trials. Oncologist. 2020
May;25(5):e816-e832. doi: 10.1634/theoncologist.2019-0783. Epub 2020 Mar 27.
PMID: 32219909; PMCID: PMC7216456.

Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE.First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers (Basel). 2020 Jun 7;12(6):1488. doi: 10.3390/cancers12061488.
PMID: 32517329